The CDC’s latest report reveals a concerning statistic: nearly one-third of youth in the U.S. have prediabetes, a condition marked by elevated blood sugar levels that precede diabetes. While this alarming figure underscores the growing public health challenge, experts are questioning the methodology and data interpretation by the CDC. Critics argue that the criteria used to define prediabetes may overestimate the prevalence among adolescents and potentially lead to unnecessary anxiety and interventions. However, the report does highlight a critical need to address lifestyle and dietary habits among young people, pointing to the broader implications for long-term health. Regardless of the debate, healthcare providers emphasize the importance of early detection and lifestyle modifications to mitigate the risk of developing type 2 diabetes. This news comes as childhood obesity rates remain high, further accentuating the need for targeted public health strategies. As the dialogue continues, the focus remains on ensuring that data-derived policies effectively address underlying health issues in America’s youth.
CBS NewsNew data shows CLYM116 reduces key IgA nephropathy biomarkers by ~70%, supporting a 12-week dosing regimen
October 24, 2026
New data released by CLIMB Bio and MabWorks reveals that their investigational drug CLYM116 significantly reduces critical biomarkers associated with IgA nephropathy by approximately 70%.